Research Use Only
This page is intended for educational and research purposes only. Apex Pep Lab products are not intended for human or animal use.
Summary
Sermorelin is a synthetic research peptide based on the first 29 amino acids of growth hormone-releasing hormone, or GHRH. GHRH is a natural signaling molecule that tells the pituitary gland to release growth hormone. In simple terms, Sermorelin is studied because it acts like the active signaling portion of GHRH, making it useful for research involving the somatotropic axis, pituitary signaling, growth hormone release, and IGF-1-related pathways.
Overview
Sermorelin, also known as GHRH(1-29)-NH2, is a synthetic analog of growth hormone-releasing hormone. It corresponds to the biologically active N-terminal fragment of human GHRH. Research literature describes Sermorelin as the shortest synthetic peptide with full biological activity of GHRH, making it an important compound for studying pituitary growth hormone release and somatotropic-axis regulation.
Research Background
Growth hormone-releasing hormone is produced in the hypothalamus and acts on the anterior pituitary gland to stimulate growth hormone secretion. Sermorelin is based on the active 1-29 amino acid region of GHRH and has been studied in relation to growth hormone release, IGF-1 signaling, pituitary reserve, endocrine feedback, and age-related changes in the somatotropic axis. Because Sermorelin acts upstream of growth hormone release, it is often discussed separately from direct growth hormone administration.
Mechanisms Studied
Research interest around Sermorelin focuses on GHRH receptor activation at the pituitary level. When GHRH receptor signaling is activated, downstream pathways can stimulate growth hormone synthesis and secretion. Research has examined Sermorelin and related GHRH analogs in relation to pulsatile growth hormone release, IGF-1 response, pituitary reserve, nocturnal growth hormone secretion, and endocrine-axis regulation.
Published Research Summary
Review literature describes Sermorelin as a 29-amino-acid analog of human GHRH and the shortest synthetic peptide with full biological activity of GHRH. Early research comparing GHRH analogs found that GHRH(1-29)-NH2 was equipotent to longer GHRH fragments in normal subjects. Other studies evaluated GHRH(1-29)-NH2 and related analogs in normal men and observed growth hormone responses after administration. Long-term research with GHRH analogs in older adults reported activation of the somatotropic axis, including changes in nocturnal growth hormone and IGF-1-related markers.
Quality & Verification
For research compounds such as Sermorelin, documentation is important. Researchers commonly review batch-specific Certificates of Analysis, HPLC purity data, mass spectrometry verification, lot identification, and compound identity testing to evaluate analytical quality and consistency. Because Sermorelin is a defined 29-amino-acid peptide, molecular identity and purity verification are especially important for research-use documentation.
References & Published Research
- Sermorelin: A Review of Its Use in the Diagnosis and Treatment of Children with Idiopathic Growth Hormone Deficiency
- Responses to Analogues of Growth Hormone-Releasing Hormone in Normal Subjects
- Synthetic Analogues of Growth Hormone-Releasing Hormone, GHRH(1-29)-NH2 and D-Ala2 GHRH(1-29)-NH2, in Normal Men
- Effect of GHRH(1-29)-NH2 on Growth Hormone Secretion in Normal Men
- Endocrine and Metabolic Effects of Long-Term Administration of GHRH(1-29)-NH2 in Age-Advanced Men and Women
- Growth Hormone Secretagogues and Sermorelin Research Context